Clementia Announces Preliminary Results of its Phase 2 Trial in Treatment of FOP

An important announcement from Clementia

The IFOPA is pleased to share this announcement from Clementia Pharmaceuticals: Top-line Results from Phase 2 Trial of Palovarotene for Treatment of Patients with FOP. Read more.

Make a Difference

Donate Connect Fundraise
Already a Member? Sign In

Sign Up for FOP Connection, Our Monthly eNewsletter